Active clinical trials for "Multiple Sclerosis"

The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Aim: to test the efficacy of this innovative cognitive remediation protocol for relapsing-remitting multiple sclerosis (RRMS) patients, characterized by a non-conventional focal high-definition transcranial direct current stimulation (HD-tDCS) on the left dorsolateral prefrontal cortex (DLPFC) to boost the effects of a computerised cognitive training (CCT) in improving frontal-executive abilities, in a randomized, double-blind, sham-controlled exploratory pilot study. Secondary objectives: assess protocol feasibility and safety; evaluate its medium/long-lasting effect; estimate the extent of changes in cognitive abilities; evaluate any neurophysiological changes; indagate any related changes in other clinic-behavioural measures. Materials: Forty-four RRMS patients with predominant deficits in information processing will be selected. They will be randomised and equally divided to: real HD-tDCS + CCT (experimental group) and sham HD-tDCS + CCT (control group). Methods: Study treatment will last 40 minutes/day, 5 day/week for 2 weeks. CCT will focus on improving fronto-executive skills. HD-tDCS will be administered on the left DLPFC with a 4x1 ring electrode placement and at an intensity of 2mA (real stimulation) for the first 20 minutes of the protocol. Pre- and post-treatment and at 3- and 6-months follow-ups, participants will undergo neuropsychological, neurological and neurophysiological measurements. To assess changes over time, a repeated-measures analysis of variance will be applied. Functional and effective cerebral network connectivity will be calculated using phase-based metrics and Granger causality analysis. The relationship between clinico-demographical measures and cognitive/behavioural/physiological measures will be assessed using the correlation coefficient. Descriptive analyses will be provided for feasibility (overall compliance) and for safety (any tDCS-related discomfort/side effect or adverse event). Expected results: an improvement in cognitive performance in both groups, boosted in the experimental arm and not confined to general frontal-cognitive abilities; potential changes would be reflected also by neurophysiological measures and in QoL. Discussion: Investigators hope to provide additional treatment tools for RRMS subjects, with a medium-long term efficacy and an extensive effect. This exploratory pilot study will help to set the rationale for future studies, providing preliminary data useful for selecting the best primary outcome and for calculating a better sample size.

This study will compare the effectiveness of a traditional, continuous walking rehabilitation program for people with MS to the novel intervention of an intermittent or interval walking rehabilitation program. Half of the participants will receive the continuous walking program while the other half will receive the novel intermittent walking program.

Background: Replications of studies employing transcranial direct stimulation (tDCS) shows great variations in physiological and behavioral outcomes. The disparity between studies is based on the expectations of getting the same cortical activity changes consistently once the procedures and current parameters have been repeated. Nevertheless, this assumption was inoperative, due to the individualized variations of numerous parameters such as: age, disease type, symptom severity, head geometry, etc. Objective: Through this clinical trial we aim to reduce the variability of the physiological and behavioral outcomes of tDCS by individualizing the current intensity and to study the neurophysiological and behavioral outcome differences between participants who receive the customized current intensity in comparison to the others who would receive a fixed dose. Methods: Based on individual patient's structural MRI images, the Electrical field (E-field) distribution can be modeled and the individualized current dose to stimulate a target region can be determined. A group of thirty persons with multiple sclerosis (PWMS) would be pseudo-randomized into three groups receiving all 3 treatments of individualized tDCS, fixed currents (2 mA), and sham tDCS. Baseline and post-intervention assessment of physiological and behavioral outcome measures will be assessed using respectively, transcranial magnetic stimulation (TMS) recruitment curve and a stop-signal task and GO/No-go test. Significant statement and clinical relevance: Individualizing the patient's tDCS current intensity will result in a better clinical outcome (i.e. more robust physiological and behavioral effects), as compared to a tDCS application that is based on a fixed current.

Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via intravascular system of quality of life and alteration of documented Advanced Muscular Sclerosis (MS). It is believed that the heterogeneous cell population which includes multipotent stem/stromal cells plus non-multipotent cellular elements are capable of immune modulation/inflammatory modulation properties. Exam of disease progression and quality of life changes will be evaluated by sophisticated mathematical non-biased MRI analysis.

The aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of Overactive bladder (OAB) in patients with multiple sclerosis.

This study involves data collection from use of the BeCare Link LLC mobile device app by subjects with Multiple Sclerosis.

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).

Specific Aims The specific aims of the study are: Primary Objective: To assess the effect of alemtuzumab on microglial activation in MS patients. The hypothesis is that alemtuzumab reduces microglial activation in MS, which may mediate its effect on reducing conversion of RRMS patients to SPMS, and its effects on cognition, including cognitive fatigue. Secondary Objective: To determine the time course of effect of alemtuzumab on microglial activation. The hypothesis is that alemtuzumab reduces microglial activation at 6 months after initiation of treatment and this effect persists and is accentuated at 18 years, i.e. after administration of the second course